Table 1 from Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer | Synapse
October 2, 2025
Table 1 from Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
Puntos clave
The analysis population includes patients with advanced breast cancer receiving no prior systemic therapy.
Key characteristics such as demographic data and baseline disease status were documented for targeted therapies.
Median ages and disease stages were compared, supporting insights into treatment efficacy.
Reflects findings on the combination therapy of gedatolisib, palbociclib, and letrozole in clinical practice.
Resumen
Patient demographic and baseline disease characteristics in the full analysis population with no prior systemic therapy for advanced breast cancer.